Skip to main content
Figure 2 | Journal of Immune Based Therapies and Vaccines

Figure 2

From: Identification of proteases employed by dendritic cells in the processing of protein purified derivative (PPD)

Figure 2

Pepstatin A inhibits the capacity of XS52 DC to present native PPD: (A) γ-irradiated XS52 DC were pulsed with PPD (100 μg/ml) in the presence or absence of each protease inhibitor (100 μg/ml pepstatin A, 100 μM DCI, or 100 μM E-64) or vehicle alone (1% DMSO or 15 mM NH4Cl). XS52 DC were then cultured for 2 days with the PPD-reactive Th1 or Th2 clone in the continuous presence of the same inhibitor or vehicle alone. Data shown are the mean ± SD (n = 3) of 3H-thymidine uptake in three representative experiments. (B) XS52 DC were incubated with each of protease inhibitor (100 μg/ml pepstatin A, 100 μM DCI, or 100 μM E-64) or vehicle alone (1% DMSO or 15 mM NH4Cl) for 16 hrs. Subsequently, cells were harvested and their viability was measured by trypan blue.

Back to article page